S9D) and treated them with either a combination of anti-IL-4 and anti-IL-13 neutralizing antibodies (αIL-4/13Ab-ILC2-SNT), or isotype control antibody (conAb-ILC2-SNT), before adding them to purified intestinal tumor M-MDSCs or splenic M-MDSCs from Apc1322T/+ mice. This evidence concerns the gene IL13 and intestinal neoplasm.